Results from the second, larger phase 2 study (N = 69) revealed a CRi rate of 39% and a PR rate of 11% in patients with relapsed FLT3-mutated AML who had not received prior FLT3 inhibitors and a CRi + PR rate of 28% in patients who had received prior FLT3 inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.